Akums Drugs and Pharmaceuticals Limited (AKUMS) reported revenue of ₹1,167 Cr and net profit of ₹101 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
AKUMS fundamentals, Fundamental score 45/100
The statements below are read from Akums Drugs and Pharmaceuticals Limited’s filed results, 13 filed quarters and 9 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Aug 9, 2026 · audited
Sales CAGR · 3Y+6.0%FY22 → FY25
Sales CAGR · 4Y+4.4%FY21 → FY25
PAT CAGR · 3Y+37.8%FY22 → FY25
PAT CAGR · 4Y—FY21 → FY25
Price · 1Y+64.5%EOD
Price CAGR · 3Y—EOD
Quarterly resultsConsolidated
₹ Cr
Jun2023
Sep2023
Dec2023
Mar2024
Jun2024
Sep2024
Dec2024
Mar2025
Jun2025
Sep2025
Dec2025
Mar2026
Jun2026Latest
YoYlatest
Sales
970
1,181
1,083
944
1,019
1,033
1,010
1,056
1,024
1,018
1,160
1,158
1,167
+13.9%
1,095
1,029
989
941
891
912
889
962
895
923
1,013
1,006
992
+10.8%
Operating profit
-125
152
94.0
3.00
128
121
121
93.9
129
94.5
147
152
175
+35.4%
OPM %
-12.9%
12.9%
8.7%
0.3%
12.6%
11.7%
12.0%
8.9%
12.6%
9.3%
12.7%
13.1%
15.0%
+2.4 pp
Other income
8.00
-21.0
10.0
10.0
7.00
17.0
14.6
17.5
26.7
32.4
34.3
35.3
30.4
+13.7%
Interest
12.0
14.0
12.0
12.0
13.0
12.0
5.13
4.54
23.1
23.3
23.7
23.9
24.8
+7.0%
Depreciation
30.0
30.0
32.0
34.0
34.0
35.0
44.5
40.0
36.9
37.9
39.6
40.1
41.1
+11.2%
Profit before tax
-159
87.0
59.0
-33.0
87.0
92.0
91.1
75.1
95.6
65.7
99.6
121
139
+45.6%
Tax %
n/a (loss)
—
—
n/a (loss)
29.9%
27.2%
27.2%
-99.1%
32.4%
35.0%
32.0%
32.9%
27.5%
-4.9 pp
Net profit
-187
33.0
195
-39.0
61.0
67.0
66.3
150
64.7
42.7
67.7
81.3
101
+56.1%
EPS (₹)
-13.16
2.22
13.54
-2.89
4.08
4.14
4.26
9.64
4.15
2.66
4.33
5.53
6.53
+57.3%
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split · n/a (loss) = tax rate undefined on a loss↔ scroll for earlier quarters
Revenue & net profit trend
last 13 quarters
RevenueNet profit
Revenue & net profit — Consolidated13 quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±3.7%· EPS surprise: no estimates source· 4 earlier quarters have no dated filing on record
Q1'27filed Sat 8 Aug 15:46 · first tradeable session Mon 10 Auggap +1.8%close +4.7%
Q4'26filed Thu 14 May 17:39 · first tradeable session Fri 15 Maygap +0.7%close −2.1%
Q3'26filed Fri 13 Feb 16:21 · first tradeable session Mon 16 Febgap +2.6%close +5.7%
Q2'26filed Thu 13 Nov 16:52 · first tradeable session Fri 14 Novgap −1.7%close −3.0%
Q1'26filed Fri 8 Aug 17:31 · first tradeable session Mon 11 Auggap +1.0%close −0.1%
Q4'25filed Mon 26 May 18:57 · first tradeable session Tue 27 Maygap +2.3%close −0.8%
Q3'25filed Thu 6 Feb 17:58 · first tradeable session Fri 7 Febgap −0.8%close −2.4%
Q2'25filed Sat 9 Nov 17:51 · first tradeable session Mon 11 Novgap −0.3%close −10.0%
Q1'25filed Sat 24 Aug 17:30 · first tradeable session Mon 26 Auggap +1.7%close −5.0%
